Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?

Blue Latitude Health

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

Products as portfolios: positioning immuno-oncology products

The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning...

Blue Latitude Health

- PMLiVE

AstraZeneca embarks on oncology research access project

Invites companies to join molecular data resource consortium

Immunotherapy in oncology

Consultant David Cooney explores the medical insights, unmet needs, and future of the vastly growing area of immunotherapy as the fourth pillar in oncology.

Blue Latitude Health

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Immunotherapy and future directions in oncology

How the field of cancer drugs is expanding as technology improves

- PMLiVE

Fertility drugs drive healthcare growth at Merck KGaA

Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links